

WE CLAIM:

- 39

6. The peptide of claim 1 having the amino acid sequence:

VRRVVRRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO: 6).

7. A composition comprising the peptide of claim 6 and a carrier.

8. The peptide of claim 1 having the amino acid sequence:

RRVVRRVRRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:7);

9. A composition comprising the peptide of claim 8 and a carrier.

10. The peptide of claim 1 having the amino acid sequence:

RVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVRVVR (SEQ ID NO:8).

11. A composition comprising the peptide of claim 10 and a carrier.

12. The peptide of claim 1 having the amino acid sequence:

RVVRVVRWVRR (SEQ ID NO:9).

13. A composition comprising the peptide of claim 12 and a carrier.

14. The peptide of claim 1 having the amino acid sequence:

RRWVRVVRVWVRVVRVVRWVRR (SEQ ID NO:10).

15. A composition comprising the peptide of claim 14 and a carrier.
16. The peptide of claim 1 having the amino acid sequence:
VRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWVRR (SEQ ID NO:11);
17. A composition comprising the peptide of claim 16 and a carrier.
18. The peptide of claim 1 having the amino acid sequence:
RVVRVVRWVRRVRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWV (SEQ
ID NO:12).
19. A composition comprising the peptide of claim 18 and a carrier.
20. The peptide of claim 1 wherein said peptide has antimicrobial activity.
21. The peptide of claim 1 wherein said peptide has antimicrobial activity in low salt.
22. The peptide of claim 1 wherein said peptide has antimicrobial activity in physiologic salt.
23. An LLP-1 peptide analog wherein said peptide is modified to optimize amphipathicity.

24. An LLP-1 peptide analog, said peptide comprising an arginine residue on said peptide's charged face, wherein said arginine residue is substituted with another amino acid residue and wherein said peptide analog comprises an amphipathic α -helical structure.

25. An LLP-1 peptide analog, said peptide comprising a tryptophan residue on said peptide's hydrophobic face, wherein said tryptophan residue is substituted with another amino acid residue and wherein said peptide analog comprises an amphipathic α -helical structure.

26. An LLP-1 peptide analog, said peptide comprising a valine residue on said peptide's hydrophobic face, wherein said valine residue is substituted with another amino acid residue and wherein said peptide analog comprises an amphipathic α -helical structure.

27. An LLP-1 peptide analog, said peptide comprising a tryptophan residue and a valine residue on said peptide's hydrophobic face, wherein said tryptophan residue and said valine residue is substituted with another amino acid residue and wherein said peptide analog comprises an amphipathic α -helical structure.

28. An LLP-1 peptide analog, said peptide comprising additional residues to increase its length, wherein said peptide analog comprises an amphipathic α -helical structure.

29. A solid phase substrate comprising at least one peptide selected from the group consisting of:

RVVRVRRVRR (SEQ ID NO:4)

RVVRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRRVVRR (SEQ ID NO:8).

35. The solid phase substrate of claim 29 wherein the peptide is RVVRVVRRWVRR (SEQ ID NO:9).

36. The solid phase substrate of claim 29 wherein the peptide is RRWVRRVRRVWRRVVRVVRWVRR (SEQ ID NO:10).

37. The solid phase substrate of claim 29 wherein the peptide is VRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWVRR (SEQ ID NO:11).

38. The solid phase substrate of claim 29 wherein the peptide is RVVRVVRRWVRRVRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWVRRV (SEQ ID NO:12).

39. The solid phase substrate of claim 29 wherein said solid phase substrate is a prosthetic device.

40. The solid phase substrate of claim 39 wherein the prosthetic device is a prosthetic joint.

41. The peptide of claim 1, said peptide comprising at least one cysteine residue.

43. A peptide-cargo complex comprising a cargo and a peptide selected from the group consisting of:

RRVRRVRRVRRVRRVRRVRR (SEQ ID NO: 5);

[illegible]

NO:8); RVVRVVRWVRR (SEQ ID NO:9); RRWVRRVRRVWRRVVRVVRWVRR (SEQ

and RVVRVVRRWVRRVRRVWRRVVRVVRWVRRVRRVWRRVVRVVRWV (SEQ ID NO:12).

45. A method for inhibiting microbial growth comprising administering an effective amount of at least one peptide selected from the group consisting of:

RRVRRVRRVRRVRRVRRVRR (SEQ ID NO: 5);

RRVVR VRRV VRRV VRRV VRRV VRRV VRRV VRRV VRRV VRRV (SEQ ID NO:7);

46. The method of claim 45 wherein said peptide inhibits microbial growth in *in vitro* cell culture.

48. The method of claim 47 wherein said peptide is administered enterally or parenterally.

49. The method of claim 45 or 47 wherein said peptide is attached to a solid phase substrate.
50. The method of claim 45 or 47 wherein said microbial growth is resistant to antibiotics.

09/05/06 09:20:00